Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human study of ABBV-706 alone and with budigalimab, carboplatin, or cisplatin in advanced solid tumors
jRCT2031230510Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of turmetabart adizutecan in Nonhematologic neoplasms, small cell lung cancer (SCLC), glioblastoma (GBM) and 7 more (6 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of participants with adverse events, Maximum observed serum/plasma concentration (Cmax) of ABBV-706 and 12 more. Started Jan 2024; status: active, not recruiting.
02
Drugs
turmetabart adizutecan
03
Conditions
Nonhematologic neoplasmssmall cell lung cancer (SCLC)glioblastoma (GBM)Oligodendroglioma (OG)astrocytoma
Beyond the preview
Go deeper on jRCT2031230510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230510.